Biomedical Advanced Research and Development Authority (BARDA)
330 C Street, SW
Room G640
Washington
D.C.
20201
United States
Tel: 202-260-1200
Fax: 202-205-4520
214 articles about Biomedical Advanced Research and Development Authority (BARDA)
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
-
America's Blood Centers Partners with BARDA to Expand Collection of Convalescent Plasma for COVID-19 Patients
4/27/2020
Community Blood Centers Nationwide Remain at the Forefront of the National Response Efforts to Increase Access to COVID-19 Convalescent Plasma [27-April-2020] WASHINGTON , April 27, 2020 /PRNewswire/ -- America's Blood Centers and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Resp
-
DiaSorin Obtains FDA Emergency Use Authorization and BARDA Funding for SARS-CoV-2 IgG Serology Kit for COVID-19 Testing in the U.S.
4/25/2020
DiaSorin announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration for the LIAISON® SARS-CoV-2 S1/S2 IgG test.
-
Cytovale Receives Additional BARDA Funding to Evaluate Rapid Sepsis Diagnostic in Persons Under Investigation (PUI) for COVID-19
4/23/2020
Expansion of BARDA funding will help fund Cytovale pilot study for innovative rapid sepsis diagnostic system that delivers results in under 10 minutes The pilot study will be conducted in partnership with Louisiana State University (LSU) and Our Lady of the Lake Regional Medical Center in Baton Rouge, LA COVID-19 patients are at high risk for sepsis, a f
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 23, 2020.
-
After leading a flurry of collaborations with multiple companies to hasten the development of vaccine candidates and treatments for COVID-19, Rick Bright, the director of BARDA, has abruptly departed his post for another position in the government.
-
Cellphire Announces Exercise by BARDA of Option 3 of Contract to Develop Platelet-Based Hemostatic
4/21/2020
Cellphire, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its third contract option valued at $33.3 million to support Cellphire's next generation platelet-based hemostatic product, Thrombosomes®, through a Phase 2 clinical trial in bleeding thrombocytopenic patients.
-
Vela Diagnostics receives BARDA funding to develop COVID-19 tests
4/20/2020
The partnership will support verification and clinical validation of RT-PCR tests to detect the COVID-19 virus.
-
As Moderna moves forward with its mRNA vaccine candidate for COVID-19, the U.S. federal government is helping accelerate the potential medication with a $483 million infusion from the Biomedical Advanced Research and Development Authority.
-
HEMEMICS Biotechnologies, Inc. Receives HHS Support to Develop Rapid Antigen, Antibody Diagnostic to Identify COVID-19 Infected Americans
4/16/2020
Hememics Biotechnologies Inc., ("Hememics" or the "Company") announced that they are partnering with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secre
-
OraSure Technologies Receives BARDA Contract for Rapid Oral Fluid Pan-SARS-Coronavirus In-home Self-test
4/6/2020
OraSure Technologies, Inc. announced it has been awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, to develop a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples.
-
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
3/25/2020
Grifols announces that it has entered into a formal collaboration with the US Biomedical Advanced Research Development Authority, the FDA and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease.
-
GenMark Awarded BARDA Grant for the Development of ePlex® RP2 Panel
3/23/2020
GenMark Diagnostics, Inc., a leading provider of automated, multiplex molecular diagnostic testing systems, announced it has been awarded a grant from the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response.
-
“What we have could be a very powerful weapon against these types of viral outbreaks or pandemics because it isn’t pathogen- or virus-specific and could be broadly relevant in these types of situations,” Gil Van Bokkelen, Ph.D., Athersys CEO, told BioSpace.
-
Cellenkos Inc. Focuses on the Development of Cell-Therapy for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS)
3/17/2020
Cellenkos Inc. , announced today that the company has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority (BARDA) to start a Phase 1/2 clinical trial with CK0802 for treatment of COVID-19 mediated acute respiratory distress syndrome (CoV-ARDS). Cellenkos will leverage its clinical experi
-
Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine
2/18/2020
- Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi's well-established recombinant technology platform to expedite a potential COVID-19 vaccine
-
Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
2/4/2020
TARRYTOWN, N.Y. , Feb. 4, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, 2019-nCoV, which was recently declared a global public health emergency by the World Health Organization.
-
Lucira Health and BARDA Execute Contract Option for $11.5 Million to Bring OTC Flu Test to Market
11/5/2019
Lucira Health, Inc., a developer of instrument-free, molecular infectious disease testing products, executed the second phase of its contract with the Biomedical Advanced Research and Development Authority (BARDA), under the Office of the Assistant Secretary of Preparedness and Response (ASPR) at the US. Department of Health and Human Services (HHS).
-
Platelet BioGenesis Receives $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure
9/30/2019
Funding will support clinical development of stem cell-derived platelet technology platform
-
Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI
6/18/2019
Atox Bio announced the Biomedical Advanced Research and Development Authority has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections.